ICU Medical, Inc. (ICUI)
| Market Cap | 3.03B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | 732,000 |
| Shares Out | 24.99M |
| EPS (ttm) | 0.03 |
| PE Ratio | 4,034.07 |
| Forward PE | 70.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 213,193 |
| Open | 123.53 |
| Previous Close | 122.85 |
| Day's Range | 119.12 - 123.53 |
| 52-Week Range | 107.00 - 160.29 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 169.00 (+39.19%) |
| Earnings Date | May 7, 2026 |
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinf... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ICUI stock is "Strong Buy." The 12-month stock price target is $169.0, which is an increase of 39.19% from the latest price.
News
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of...
ICU Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has evolved into a global pure-play infusion leader, leveraging innovation and market consolidation for growth. Consumables and infusion systems segments are driving reliable earnings, with new products and software enhancing value. Margin expansion, tariff refunds, and share repurchases are key financial priorities.
ICU Medical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management reaffirmed EBITDA guidance and mid-single-digit growth for consumables and systems, with margin expansion expected from integration and operational improvements. Pump upgrades and software innovation are key growth drivers, while portfolio optimization and free cash flow improvement remain priorities.
ICU Medical Transcript: 47th Annual Raymond James Institutional Investor Conference
A leading infusion therapy company highlighted its strong market position, ongoing innovation, and financial recovery post-acquisition. New unified pump platforms and incremental consumables innovation are driving growth, with margin expansion and improved cash flow expected as integration and tariff costs decline.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its particip...
ICU Medical Earnings Call Transcript: Q4 2025
Q4 2025 saw 2% organic revenue growth and strong operational results in consumables and systems, despite reported declines from JV deconsolidation and tariff headwinds. 2026 guidance calls for low- to mid-single-digit organic growth, margin expansion, and improved free cash flow as integration projects conclude.
ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance
SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
ICU Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
A focused IV therapy company is leveraging innovation, strategic M&A, and targeted market niches to drive growth and margin improvement. New integrated pump systems and consumables are fueling commercial momentum, with financials and operational integration nearing key targets.
ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company...
ICU Medical Transcript: Piper Sandler 37th Annual Healthcare Conference
U.S. hospital volumes and capital spending remain healthy, supporting steady growth in consumables and infusion pumps. Integrated pump and software solutions are driving competitive wins, with a major pump replacement cycle expected to start in late 2026. Margin improvements and debt reduction continue, with future focus on software integration and potential stock buybacks.
ICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN CLEMENTE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company...
ICU Medical Earnings Call Transcript: Q3 2025
Q3 saw 5% organic revenue growth, margin expansion, and strong cash flow, with raised full-year guidance for EBITDA and EPS. Consumables and IV systems segments achieved record sales, while tariffs and integration costs remain key headwinds.
ICU Medical Announces Third Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Third Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
ICU Medical Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Leadership is confident in future growth, focusing on consumables and IV systems, with innovation and regulatory compliance as key priorities. Financial guidance reflects tariff and divestiture impacts, with gross margin expansion and operational efficiencies expected. Home care and leverage reduction are strategic focuses.
ICU Medical Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Strong utilization and competitive wins are driving growth in consumables and infusion systems, with new product approvals and software integration providing further upside. Financial guidance reflects tariff impacts and portfolio changes, while margin expansion is supported by scale and cost initiatives.
ICU Medical Earnings Call Transcript: Q2 2025
Q2 2025 saw 2% organic revenue growth, record Consumables sales, and 10% higher adjusted EBITDA, with gross margin expansion driven by the IV Solutions JV. Full-year guidance was narrowed due to tariff headwinds, but sequential growth is expected in key segments.
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICU Medical, Inc. (ICUI) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Attorney Advertising Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICU Medical, Inc. ("ICU Medical...
ICU Medical, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
BOSTON, MA / ACCESS Newswire / May 8, 2025 / Block & Leviton is investigating ICU Medical, Inc. (Nasdaq:ICUI) for potential securities law violations. Investors who have lost money in their ICU Medica...
ICU Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw 10% constant currency revenue growth, strong EBITDA and EPS gains, and robust cash flow, with all segments contributing. Guidance for FY 2025 remains unchanged despite tariff headwinds, with mitigation strategies and currency offsets expected to limit impact.
ICU Medical Announces First Quarter 2025 Results
SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial resu...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICU Medical, Inc. (ICUI) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Attorney Advertising Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICU Medical, Inc. ("ICU Medical...